Categories Earnings, Energy

ReneSola (NYSE: SOL): Q3 2019 Earnings Snapshot

— ReneSola Ltd. (NYSE: SOL) reported its third-quarter 2019 earnings of $0.06 per share versus $0.05 per share expected.

— Net revenue soared by 252% year-over-year to $65.96 million versus $20.5 million expected.

Earnings Update by AlphaStreet

— Revenue from Project Development was largely driven by the sale of the 55MW portfolio in Poland. Energy sales were mostly from the 67.8 million kWh generated by its rooftop DG projects in China.

— The total project pipeline of 1.1 GW is down from 1.4 GW last quarter, as is its late-stage pipeline, which decreased to 399 MW from 714 MW in Q2.

— Looking ahead into the fourth quarter, the company expects revenue to be in the range of $45-50 million compared to the consensus estimates of $57.7 million. The gross margin is predicted to be 10-15%.

— For the full year 2019, revenue is expected to be in the range of $130-140 million compared to the consensus estimates of $104.8 million. The gross margin is anticipated to be 20-25%.

— In addition, the company appointed Yumin Liu as CEO, effective December 4, 2019. Shelley Xu, who served as CEO since July 2019, left ReneSola to pursue other opportunities.

— Ke Chen was appointed to serve as CFO, effective immediately. Chen will continue to serve on the board. Xiaoliang Liang, who had served as CFO since June 2018, also left ReneSola to pursue other opportunities.

— The company’s corporate headquarters will be moved to Stamford, Connecticut, USA. This is in order to align its structure with the new leadership team, its growing focus on global markets, and its US stock listing.

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

Cost reduction has become a priority for FedEx (FDX) after a challenging quarter

Shares of FedEx Corporation (NYSE: FDX) were up 1% on Tuesday. The stock has dropped 44% year-to-date and 34% over the past 12 months. The company delivered mixed results for

Prime Medicine is the next big biotech to pursue IPO. Here’s all you need to know

After a soft start to the year, the IPO market has witnessed muted activity so far though a few big companies entered the stock market. On the heels of AIG

Stock Watch: Is Darden Restaurants a good buy after earnings?

After a prolonged slowdown, the restaurant industry is returning to normal patterns but macroeconomic uncertainties and high inflation are currently playing spoilsport for it. While the pandemic-related slump forced many

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top